secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001159036-23-000056
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme Q3 royalty revenue up 15% to $114.4M; raises 2023 EBITDA & EPS guidance
--------------------------------------------------------------------------------

- GAAP diluted EPS $0.61, non-GAAP $0.75; royalty revenue $114.4M (+15% YoY).
- Total revenue $216M (+3% YoY); operating income $88.3M vs $83.3M.
- Accelerates remaining $250M share repurchase into 2023 via ASR (immediate).
- Raises 2023 EBITDA guidance to $430-445M, non-GAAP EPS to $2.70-2.80.
- Partner milestones: positive CheckMate-67T, Phesgo Japan approval, Tecentriq SC US launch delay to 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903623000056/0001159036-23-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903623000056/halo-20231106.htm
  HTML page:      https://secwatch.observer/filing/0001159036-23-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer